Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies
Open Access
- 1 August 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 95 (5), 627-633
- https://doi.org/10.1038/sj.bjc.6603300
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistryThe Journal of Pathology, 2005
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in theTP53gene on survival in patients with advanced ovarian carcinomaHuman Mutation, 2004
- Critical evaluation of p53 as a prognostic marker in ovarian cancerExpert Reviews in Molecular Medicine, 2004
- Distinct subtypes of serous ovarian carcinoma identified by p53 determination☆Gynecologic Oncology, 2003
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatinCancer Letters, 2003
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- The significance of p53 mutation and over-expression in ovarian cancer prognosisInternational Journal of Gynecologic Cancer, 1996
- ras-Induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutationCell, 1992